Teams aim to develop numerous degrader-antibody conjugates to selectively kill cancer cells.
Nurix Therapeutics and Seagan revealed in a press release their intentions to develop a portfolio of degrader-antibody conjugates (DAC) with the focus of eliminating cancer cells. In order to achieve this goal, the organizations plan on combining ADC with targeted protein degradation (TPD), hoping to create drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.
Under the agreement, Nurix will receive an upfront payment of $60 million, potentially reaching $3.4 billion upon the completion of various milestones.
“By combining the tissue and tumor specificity of antibodies with highly potent and catalytic targeted degradation of cancer driver proteins, we believe that DACs may represent a next generation of cancer medicine for a wide range of solid tumors and hematologic malignancies,” said Arthur T. Sands, MD, PhD, president, CEO, Nurix. “With Seagen, our strategic goal is to advance ADC technology to the next level to provide patients with new DAC drugs that deliver greater anti-tumor efficacy and safety compared to currently available agents.”
Reference: Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics. Globe Newswire. September 7, 2023. Accessed September 7, 2023. https://www.globenewswire.com/news-release/2023/09/07/2739169/0/en/Nurix-Announces-Strategic-Collaboration-with-Seagen-Combining-Industry-Leading-Technologies-of-Targeted-Protein-Degradation-and-Antibody-Drug-Conjugation-to-Advance-an-Innovative-N.html
Source link
#Nurix #Seagan #Set #Collaborate #Class #Cancer #Therapeutics
